GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » EV-to-EBITDA

Beryl Drugs (BOM:524606) EV-to-EBITDA : 6.76 (As of Jun. 03, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beryl Drugs's enterprise value is ₹197.8 Mil. Beryl Drugs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹29.2 Mil. Therefore, Beryl Drugs's EV-to-EBITDA for today is 6.76.

The historical rank and industry rank for Beryl Drugs's EV-to-EBITDA or its related term are showing as below:

BOM:524606' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.16   Med: 6.18   Max: 30.69
Current: 6.76

During the past 13 years, the highest EV-to-EBITDA of Beryl Drugs was 30.69. The lowest was 1.16. And the median was 6.18.

BOM:524606's EV-to-EBITDA is ranked better than
81.13% of 710 companies
in the Drug Manufacturers industry
Industry Median: 14.455 vs BOM:524606: 6.76

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Beryl Drugs's stock price is ₹31.53. Beryl Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹2.330. Therefore, Beryl Drugs's PE Ratio for today is 13.53.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Beryl Drugs EV-to-EBITDA Historical Data

The historical data trend for Beryl Drugs's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beryl Drugs EV-to-EBITDA Chart

Beryl Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.88 6.00 3.82 17.84 4.57

Beryl Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.03 4.57 3.02 5.18 3.83

Competitive Comparison of Beryl Drugs's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's EV-to-EBITDA falls into.



Beryl Drugs EV-to-EBITDA Calculation

Beryl Drugs's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=197.776/29.244
=6.76

Beryl Drugs's current Enterprise Value is ₹197.8 Mil.
Beryl Drugs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹29.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beryl Drugs  (BOM:524606) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Beryl Drugs's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=31.53/2.330
=13.53

Beryl Drugs's share price for today is ₹31.53.
Beryl Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.330.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Beryl Drugs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs (BOM:524606) Business Description

Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines